Fresenius Debuts Subcutaneous Tocilizumab Biosimilar In US
Launches SC Version Of Tyenne Alongside Existing Intravenous Presentation
Executive Summary
Fresenius Kabi has become the first firm to market a subcutaneous tocilizumab biosimilar in the US, introducing an SC version of its Tyenne rival to Actemra just a couple of months after the intravenous launch.